Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GBIO |
---|---|---|
09:32 ET | 631 | 2.97 |
09:34 ET | 100 | 3.0015 |
09:36 ET | 2353 | 2.95 |
09:43 ET | 100 | 2.96 |
09:45 ET | 2012 | 2.92 |
09:48 ET | 200 | 2.92 |
09:50 ET | 315 | 2.92 |
09:52 ET | 378 | 2.91 |
09:54 ET | 100 | 2.92 |
09:56 ET | 716 | 2.91 |
09:59 ET | 1700 | 2.925 |
10:01 ET | 162 | 2.92 |
10:03 ET | 790 | 2.9274 |
10:08 ET | 300 | 2.95 |
10:10 ET | 400 | 2.94 |
10:21 ET | 100 | 2.95 |
10:55 ET | 200 | 2.99 |
11:04 ET | 100 | 2.96 |
11:06 ET | 200 | 2.99 |
11:09 ET | 600 | 2.9751 |
11:47 ET | 100 | 2.99 |
12:07 ET | 375 | 2.9909 |
12:36 ET | 100 | 3.035 |
12:43 ET | 425 | 3.0249 |
01:14 ET | 500 | 3.0474 |
01:21 ET | 1989 | 3.08 |
01:24 ET | 2200 | 3.1 |
01:39 ET | 175 | 3.0909 |
01:42 ET | 150 | 3.0949 |
01:44 ET | 328 | 3.0927 |
01:48 ET | 3860 | 3.14 |
01:50 ET | 467 | 3.1564 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Generation Bio Co | 216.9M | -1.2x | --- |
Quantum-Si Inc | 209.9M | -2.3x | --- |
Design Therapeutics Inc | 217.5M | -3.8x | --- |
Opthea Ltd | 214.3M | -1.0x | --- |
Boundless Bio Inc | 214.1M | 0.0x | --- |
Candel Therapeutics Inc | 212.8M | -5.9x | --- |
Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $216.9M |
---|---|
Revenue (TTM) | $10.0M |
Shares Outstanding | 66.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.87 |
EPS | $-2.56 |
Book Value | $3.07 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | 21.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,820.04% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.